AMLX - Earnings call 3 2023 | Amylyx Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning. My name is Keith, and I will be your conference operator today. At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals Third Quarter 2023 Earnings Conference Call. [Operator Instructions] Please be advised this call is being recorded at the company's request. I would now like to turn the conference over to Lindsey Allen, Head of Investor Relations and Communications. Please proceed, ma'am.

Lindsey Allen

you XXXX us earnings. thank our to and quarter third morning, for today joining discuss Good Chief Jim With Cohen our our and on Justin Officer; me the Klee, co-CEO, call Margaret Financial our Chief Frates, are Josh Commercial Officer. and Olinger,

I the are facts begin, safe ALBRIOZA, Litigation remind with to to provisions to, that on expectations of made are make forward-looking XXXX. like Securities statements call that and pursuant our everyone on based plans information statements presented RELYVRIO would a statements clinical this results any are developments SEC our expectations from Private those the harbor outlook Reform These the and made and current are our our to we we respect differ and Before set with statements not of forward-looking that statements or regarding our Act expected may current and not marketing business including other future and that include, with and in but filings we and limited those result beliefs, and uncertainties historical our or and by regulatory events as SEC. filings the recent could make and most any performance. Actual forth planned any thereof; factors, other and the timing implied strategy expressed materially risks, various expected are financial of trials

and forward-looking unless are disclaims any required You these reliance obligation statements, law. Amylyx place to cautioned not such by to any on update statements undue

to the over call I turn Justin. will Now

Justin Klee

and Lindsey, you, morning. Thank good

of in quarters what U.S. proud ALS, are here sit As X launch full our we we have accomplished. we into

treated. need ALS the to on focused improve transform do keenly to is the help way also work we and are still that We

Our progress with continues. RELYVRIO

third XXXX, launch. the We the As there ALS, product and RELYVRIO the first quarters people $XXX.X taking roughly of $XXX.X in full with X revenues in generated million U.S. in net quarter million were of X,XXX in living XX, September

with quickly engagement adopted at pleased ALS with how incredibly centers ROLIVRIO been key We are our and clinicians. has with

these living expanding those to in from many do clinicians efforts on roughly points in unaware While receive half the least we of any given new who work now may is our within RELYVRIO reach hear from be of our continue at focus our beyond clinicians and grow XX,XXX ALS We and time. provide field the benefits today on call we key that that prescribe centers, are to research market. you the as will to to with top to centers will experience focus based that additional towards we that taking are care ALS we not recognize message all our RELYVRIO will fact people people have the specialize our will of that RELYVRIO. A that continuing take commercial it look that likely goal ALS and are time additional details. at evolve transform the data as to Margaret yet we our PHOENIX

term and on As pipeline delivering on long diseases. for in and a near investing commercial goals both organization, our an focused R&D focused the the neurodegenerative are with term on we treating

of our top report the in well, to from now XXX study progressing data second participant the we Importantly, PHOENIX and line expect quarter study is XXXX.

review We data provide a was that the last month. our data medical RELYVRIO. conclusions will and presented Consortium continue confidence prominent for published survival data have details CENTAUR and reaffirm journal ALS at peer-reviewed from confident Northeast in review we recently also meeting in will study. to additional be key Josh the He design that the the the from of we share execution in the pipeline PHOENIX, on

approval RELYVRIO in with the full conditions from we and our approval the reminder, the received September for FDA basis that Canada. CENTAUR study a in for As XXXX was the late

also bringing people living to the ALS benefits We outside more U.S. worldwide. Canada RELYVRIO of and with than XXX,XXX committed remain to the the

is PHOENIX to in possible. from plan data the as supportive, seek Union we Assuming approval as the quickly European

no key for Israel to and world In in access to to around we transform to and wait. interact is did shift time disease to as know symptom addition, ALS we ALS meaningful management people with explore in this Japan. care opportunities gives hard we stakeholders from standard us with like living France, interventions, accelerate because with engaging working team the a are RELYVRIO to start with the of we opportunity our continue regulators have and to

there opportunities plans to throughout ahead U.S. and in thousands share Margaret the many U.S. detail launches with help turn now pleased us of people the call date, will our Canada. While commercial the we've are more for to progress and Canada to of over to and world. I so we the growth the additional on some are clear made and and in

Margaret Olinger

you. Thank

time, in in detail RELYVRIO a some be growth, roughly Justin up that new hard with at the of I we and second engagement given As plans prescriptions and quarter. cadence we are ended of from With RELYVRIO strong, written quarter our living we the end will specific roughly remains steady taking the any and at third working saw to this least the prescribers among X,XXX shortly. The quarter. our with accelerate goal mentioned, interest will X,XXX of ALS at people the people U.S., on XX,XXX the

about in In weeks addition, fill for living times were the with enrolling quarter. people down ALS X to

in growth this evolved about we of primarily think for our by was adds net has quarter As slowdown the this driven reasons. discontinuations year, variety increased how a

which initiatives, implementing on few begun already in have touch We educational a minutes. I will new

in clinician of our for currently aspects are support data the and PHOENIX's preparation updated We believe and of and robust program awareness, we results demand will greater addition, help reinforce greater developing marketing launch all duration PHOENIX. use. available with engagement an In of

these is data RELYVRIO with that significantly hope further people demonstrate living Our that will can ALS. impact

XXX at vast the prescribers prescriptions. majority major roughly ALS prescriptions all centers, Turning approximately to XX and remain representing mostly concentrated of quarter. representing of half Prescribing the prescribers approximately with RELYVRIO

to And the launch. clear roughly centers that these into opportunity of at roughly We the least are early data RELYVRIO. top X group on treated taking people at of use continue profile. and at of the and shows growth, pleased XX% about active just educate, full X only like is continued for a a as our centers reiterate research living RELYVRIO, approved ALS of our There ALS of X/X I these as core still well The to taken prescribing importance on RELYVRIO. XX% centers, U.S. riders RELYVRIO as have treatment and top were messaging were quarters people these in said, centers safety are we optimize on including patients drug. were actively And the our in clinics efficacy, RELYVRIO's staying of the with

that mentioned, received people ALS. through experience clinicians also care Justin from field with we roughly not As in specialize in of the all research in ALS have further learned market half do that

the group For is part, most this RELYVRIO. not prescribing

as treatment. after discontinuations. both are comparing are our rate believe enhancing out rolling source on These the to of our U.S. with of key developing group addressable, function and and some nonpersonal We X future marketing Canada, the optimizing digital field be survival. therapy include presence, both back initiation months and increasing after benefits and public, discontinued X starting taking U.S. In be RELYVRIO in to still people growth. Circling both prescribers this new in our we'll a discontinuations RELYVRIO and are insured our in to ALS, potential of reach unaware remain We may its view especially when people initiatives Canada. strategy. roughly efforts of of XX% patients, We months XX% the on on therapy private who

Our has importance the educate made remaining Canadian substantial on on team therapy. to efforts of

improve the that system, system it we can is the U.S. different in our discontinuation believe rate. Canada, leverage including in Canadian our the do a concentrated fact clearly U.S. While the learnings we from is more and

are and deploy off Operationally, benefits their from prepared with clinicians to have summarize, they in and and RELYVRIO able on right believe of optimistic interest the with major will start we ALS and to of with the so U.S. Overall, Canada set the patients. We significant the a in that begun therapy We to is educate result duration our people are key drug, in delivering messages with them, is are expectations are their strong offices learnings RELYVRIO from to our is U.S. expectations well-tolerated use. To team in ALS centers. quickly. educational a efforts engagement the additional to living we and start increased prescribing and the

X on that our strategy focused goals commercial We going drive will are forward.

to we engaging segment to optimizing are with and the to maintain our First, business. key that approach grow of clinicians continue

will to their living take caregivers programs our and we build to Second, insights appropriate and educate ALS And third, learnings utilization centers. the increase we the awareness U.S. Canada our with from of on key persistency. in outside and and people among the will to support clinicians

do, quarter. approximately will the work U.S. also over to turn great living are [ have people approximately We in a people ] but ALS the more off Jim living third with now of financial XX,XXX X,XXX be and for the our honored to and results serve continue start to more more ALS to to and in to pleased Canada. I we the call to with discuss

James Frates

Margaret, Thanks, and morning. good

to top we RELYVRIO. remain have the As and heard, the committed centers. engagement among and excellent for ALS and penetration we you've an optimistic potential

long-term focus profitable prospects PHOENIX in success we're data, our PHOENIX our next As we and out reads focused the of second to when business. In being adapt quarter of and year. meantime, in we're on confident prepared for the await the

results for revenue million of the XXXX, quarter third million the net second turn Now of $XXX.X to of coming quarter. for that quarter revenues revenues the the let majority Net compared vast for from were product States. the United me with financial to the $XX.X product

Our results were factors. a number of impacted by

what of slightly X% below XX% with Gross-to-net goods, versus was our a free QX. to there adjustments approximately long-term earlier, similar XX% were QX. over higher the mentioned quarter. addition is In ALS This number was people and to in in also receiving roughly expectations Margaret living

chargebacks we and We rebates had anticipated. than continued to see lower

low the helped settle the end of were of net the to to of completion quarter. pharmacies were revenues. X% we obligations a roughly X as at approximately similar and weeks we've of forward, our rate second expected, seen QX scrap gross-to-net expect $X.X our levels at the in will quarters. expectations. of the range our in was Cost Going is specialty XX% inventory by the million in range quarter with sales for within of previous in channel XX%. Inventory quarter, product royalty of what This

Going forward, million we Research for quarter. the of development expenses expect the COGS to sales. X% of and range to XX% be were in $XX

other R&D or we start programs compared as in Phase to our portfolio. Selling, million in range expenses, advance III in expect to to for million new in expenses, should the million the $XX quarter mainly personnel enrolling driven in $XX.X expenses increases of fourth global in marketing $XX PSP You additional participants be trial QX. million quarter. general administrative and contributions the and was quarter were SG&A, charitable and in in the by increase $XX.X our The

quarter. be fourth strong in $XX.X quarter We a net to line. the row this expect our in These representing for SG&A to results million led profitability. third in generated expenses range We a income, bottom of

quarter cash the of $XXX ended short-term with we X million investments debt. and and Finally,

in PHOENIX our Our as quarter, situated the we pleased and $XX $XX assets paid with the We're position, million trial. and during million well as remains balance QX. completion financial payables down sheet we increased await strong in of the are our approximately strong we

deliver of discuss value bottom among for treatments Our line, Josh line. I'll continue top We're interest our centers. top the provide call ALS the ability much-needed R&D launch to invest over additional grow has in in on our diseases updates. to our pipeline neurodegenerative to shown and program confident the to our to RELYVRIO turn now and our in to

Joshua Cohen

to across Thanks, antisense is known PSP phenylbutyrate palsy cell AMXXXXX of we prevent advancing as Wolfram other oligonucleotide evaluate taurursodiol may trials work RELYVRIO, or clinical and sodium also ALS. advancing to AMXXXXX, diseases, and Jim. AMXXXXX as in or are syndrome an in death. actively and applicability and We synergistically have supranuclear slow believe progressive comprised well neurodegenerative as

and Phase We to presented feedback III on received there. ORION of trial positive ORION the launch community PSP are design the this Conference year. We at the study in during XXXX from the track recently AMXXXXX Neuro

to and Additionally, in report II continue trial progress Wolfram in Phase results syndrome expect to we XXXX. our

presented preclinical calpain-X We and to clinic XXXX. the targeting oligonucleotide expect candidate. NEALS enter are through our AMXXXXX, in IND-enabling also recently at antisense this on the studies We advancing data conference

this this about a diagnosis addition allows goal advancing a program takes shared new this full from which and better earlier. intend in that programs, program In is We initial we for a we tool these to earlier conducting to diagnosis of also We treatment that suggests experimentation biomarker diagnose to at earlier set therapeutic Current results to are provide data NEALS that outcomes. are a new The in advancing ALS, of result of may year. year. XXXX. ALS composite create

been RELYVRIO. of we on working a new intellectual new allow formulation for This mask For may several have also years, formulation taste property.

planning to testing XXXX. for formulation Phase I an innovative and are in conduct We file IND our

trial also This to RELYVRIO first post-hoc RELYVRIO treatment function to quarter, publish survival continued as data. well a the only demonstrate benefit as in a in is a ALS approved significant we for analysis. a clinical statistically and benefit in longer-term

post-hoc neurology. overall and survival in clinical demonstrated group comparing median of a the trial in group was the the published results analysis clinical months than the control of of trial analysis translational this AMXXXXX in clinical XX.X an in survival historical recently, the long-term was Just to participants trial The that historical the annals longer group.

finally, -- are on readout we PHOENIX, our approach for focused top setup the we in for as line success. our and As confident we execution

is randomized, study placebo-controlled based meeting success its the design was CENTAUR, in travel outcome. primary which we on a saw prespecified First,

design entry broader allow shown Second, to the at population criteria, a study similar for a the very that presented enrolled while NEALS. we in to CENTAUR, poster are as

in executed to Interest and start, and PHOENIX X data and in QX medicine planned expected and can off pleased high, and we a an with simultaneously have with commonly goal enrolled we participants X neurodegenerative investigators size Xx what time other most date Overall, people in far launch commercial of we XXX in with RELYVRIO if of the serve so to a are the progress PSP with organization is closing, our as both is CENTAUR exploring to well ALS. substantial from our XXXX roughly Lastly, our achieved and the among step. rofamzyndrome. including ahead we great have await launch made the strong us, used and very diseases, our opportunity We enrolled we have becoming and help eagerly the randomization towards now of RELYVRIO our pipeline. per line. In are

to call take happy be Operator, we'd the questions. Q&A. Now to your open up please

Operator

[Operator Instructions] first And from Goldman the Corinne Jenkins Sachs. comes with question

Corinne Jenkins

primarily the ultimately that or early kind to as a you're you to you just seeing? of adverse Are change the respect clarify follow-on type on during of disease to from in a on seeing you diagnosis? can Or So are any help drug kind the these are now events, little that? time with Or bit progression particularly discontinuations in patients the patients dying? that's due on coming launch, versus of

Margaret Olinger

much question. very the Yes. Thank you is for Margaret. This

connected therapies. discontinuations, on But sadly. remember So to many variety state reasons there's the people of important yes, that it's it's why discontinue ALS really in ways, the a disease to

from designed really for our tactics deploying key efficacy the we're because including learnings focused long-term being importance on help where based of therapy discontinuations, Canada, mentioned, of of long we the as types taking to heavily these on is on on remaining the therapy the term. lower So rate we

regarding on. So second that's the And focused highly mix therapies. of what we're question

that were We continue more months. on probably slightly mix mix coming with third of the to have in would patients, a higher in coming But quarter, last define patients. therapies, the that see on as a X been we've we patients that I of of diagnosed a mix patients and prevalent the seen diagnosed say therapy newly patients

Justin Klee

the And I'll as thing maybe well. there Yes. only add

we're X the months we're to discontinuation In the Canada, XX% remaining going however, roughly therapy. people U.S., seeing on XX%. roughly at seeing of in Just specifically,

we tells that this. can is we believe impact that what So us this

be what do going to so over quarters. to And the trying coming that's we're

Corinne Jenkins

of know of what sort like the indication? do in the rates for And whole, therapy is drugs we industry kind of duration broader or the of for standard ALS cost that discontinuation what's the therapies on average

Joshua Cohen

of our we're and Canada data kind there, market. to see talk other pulling this probably therapies best-in-class data on on much And But Yes. area think of goal we the to It's is an be can we're all continue we opportunity Obviously, to here. some seeing about a is and little different therapies and continue I again, at the different looking say. too to hard the don't believe grow.

Margaret Olinger

and sorry, that. say to Yes, add I to I going just -- just and would was

We mission to moving continue believe therapy patients get therapy that on stay and longer, and who better our objective earlier we'll on have and certainly outcomes, that's forward. patient

Corinne Jenkins

expect growth guess, you as first be you're this, we quarter? you fourth half to can big this Or should of comment in And I quickly guys would the acceleration if of well. toggle kind trends could to how we in see the expect patient helpful be given this then particular, into a in And seeing the year? there factor Okay. on

Joshua Cohen

top will comment in quarters XX% RELYVRIO, Yes, say, of therapy what it's number Margaret and But have centers on rolling of on are initiatives that impact we I'd we out probably people say the while I how on we and next that early any a the XX% hope people in to will mentioned, roughly things. land. we're think, -- have of of people I as ALS or therapy. can with percent

of So la specialist. share And that. people found not to then continue we we seen we're are opportunity optimizing what and see actually as is big by there, going we roughly a half a

well see to and beyond have discontinuation to on, worked to that there. get I those U.S. And so seen broader think to use as try just a the the as tactics regions. on there's hopefully then in too, growth going finally, ALS we And key touched the opportunity in we're RELYVRIO big And centers. continue we've side,

Justin Klee

and time will for Josh have U.S. there we mean we treatment the ALS. have see which that I And short, bringing have results, back and I from long-term growth milestone PHOENIX the it studies. opportunities. picture, any was we positive end opportunities, near-term we study the who growth roughly in have the X,XXX think think at in the X while great one a Karen, would on the the are have XX,XXX community, time outlining, huge quarter, opportunities people just we of of people a treatment as as growth also And the be results ALS also first to

right the us have have ahead So we we think trial and I accelerate great will we results, think further that. of opportunities growth now, which PHOENIX

Operator

question from Meacham of Bank next the with Geoff comes And America.

Geoffrey Meacham

had few. a Just

PHOENIX, on compassionate other geographies. to could think with a mid-XX% Just versus hairs, So Europe, the know second but is rate? thinking a use revenue on How use faster going does much Or these? Is one it's approval from expect the want but full specific event a indicator, ultimate leading in see the as kind And guidance? maybe some based is first that France of to demand? more we get and of I into question you that splitting guys did guess, just about I you incremental XQ? formal -- is compassionate be about of

Joshua Cohen

Yes.

first. So maybe on PHOENIX

we first maybe mid- said year I otherwise. think over ago at this or point a

just So specific about over pass more then case it getting of I getting the impact nearer use we're the to closer there. Jim readout think talk compassionate and revenue. to to And on do it's a as I'll

James Frates

up last France Yes. late just month. We in started

have it in if centers centers to that ultimate to And we important see more as the and additionally, be That remains it then be do in than we we going United the an -- those concentrated see I incremental be RELYVRIO. key get this think through through they States. revenue said, with and demand it opportunity experienced seen there. interesting, is be Europe will it So it see are to hopefully, tend XXXX be will to the approval.

important for frankly, the for it access will but it's while Europe. us the our So the given be -- driver incremental, will looking States, in But get we're United main full is approval be of revenues to to patients. size, certainly in it

Geoffrey Meacham

of think guys just a do to I Europe, hit? set functional do quick. think for through And on But you. you for could in Got you data When know hit for just you year? would a now. to next real you back-and-forth think have have PHOENIX, follow-up filing you process been to as that OS theoretically, you the wait Or you file if about

Joshua Cohen

Yes.

we as top PHOENIX certainly, especially regulators. ultimately, But can. say, our will with I'll as line to approval speak of quickly never positive intention we the So can the coming or forward is push out project want results, readout, for we possibly towards

Justin Klee

in adding, results trial deal And and just will again, mean, participant disease will think have And I team ALS the to overstate be remain a the a think in clinical we the those much be our I been historical a there's it's study. XXX major It's further -- execution your milestone hard of think is that positive that confident Yes. community, for to it's I I questions, think design I the so to too, failure, executing. a community. big what where opportunity X the studies for study,

Operator

Umer Raffat question next the from comes with Evercore And ISI.

Umer Raffat

X. have I

not Let street looks I because with summer on it you puzzles street that have can coincided on around on sense expand frame. feel may fact ready ready you I picking been only me to July like discontinuations end, just perhaps. you you for data vendors It a the IMS Symphony you this do and the I also the restriction like massive really have -- looks time how the me like was look feel your channels slowdown? with implemented like just How which this from limited If really it start this how and that? had could today. but Because for on up pattern at communication

Joshua Cohen

start. maybe yes, I'll Well,

launch our model. distribution limited have to always intention the So was at

we coming had the had there everyone areas that out, that. of data February we so some where is and in we so updated thought addressed one And identified we

any is February. that as the that people of very here, in back we we're But was here. we're that time. growth helping reiterate, us. at opportunities I quarter. disease is there trying proud with X,XXX really ahead the thing of have X of too, long-term thing last XX,XXX So think I'll again, people though, the We're the space that important ALS And the are say, And transform huge end most I'll to

remarks, interventions, is to symptom on start not meaningful we're As focus that's to on happen I overnight, further think going job to historically and to -- even so my but ALS focused a we've but said identified to the the landscape. transform trying great in we've far, shift management, we done also opportunities field

we think great growth we have So opportunities ahead of us.

Umer Raffat

Got just it. follow And up. me let

again XXX I where discontinuations up picks to in on, in number ad X,XXX which don't if on XQ, the I might it's another XQ. may hard in out about new feel put XQ the know, quarter-over-quarter Just Because may new feel Is had to that's XXX have am that XQ. a What since a, about XX% therapy up you It's meaningfully right XX%, from And makes XQ. very starts right might track XXX calculating net launch? like discontinuation. Am I XQ for on just versus right? model it also the started patients be was you dropped have to add in unless the I discontinuations it have in your about there? your case, if in I But is not very secondly, discontinuations. I meaningful about

Joshua Cohen

are XX,XXX living ALS roughly United commented haven't back. in we people any of circle maybe with on just those Maybe States. There the but metrics, to

X,XXX have therapy. on We

what an to going see here grow. that's continue to do. certainly And we're to to be trying opportunity we So out

we think tactics we think of shared several I that that. will achieve the

Justin Klee

that And designed our again, are initiatives Yes. transforming think I at, ALS.

think the broader We far the found we in there community. are neurology we the in further where have market, people initiatives centers top in help opportunity to there's more that

And our further to so as And again, the that's can we therapy we we Canada, that that staying disease initiatives we showed can we on show do strategies think for longer matters. of think there's use transforming in space. great part awareness. And

people terms those. on coming we have in of all So of as as well in to on your both to treatment, answer staying great new address growth sort of strategies think question on we

James Frates

Yes.

just me Let number X. take

remarks, as into actually, mentioned steady QX. think Margaret prescriptions your QX you actually I had from we've do in calculations, her new

steady while QX to new We've adds. about touched always we the remarks. talked and we we adds. And -- that, from obviously want in change call, last we've into bit model that that QX, So Certainly, of the no little in about and our growth terms time. and because it seen a is, accelerated we we there. X we've of drop more decline on and slowed new until through get move There's just not about seen has another real major months see like the distinctive months discontinuation in down steady a This that we slightly here. or can't but it's a off been as point what right cautioned model discontinuations X right, growth

So quarter. That's over little higher gotten that rate data through discontinuation last last the in couple than It's the different Canada. months. CENTAUR we've tracking been a of

in our hopefully So we our This tactics bit tactics, growth get an a little first has actually far and of as on adjustment lean this very can launch what a we been we think months. that adjust into is think back X so more and to solid seeing here again. I

Operator

And the next question comes Partners. Marc Goodman from Leerink with

Marc Goodman

versus can to give of we you what just about? talked Maybe how October sense give flavor a Yes. for trends a us everybody went

Joshua Cohen

terms there's We're Yes. things that is And are in certainly, But Margaret there continuing. revolutionary We things of I'd what of the adds usually to out don't we're certainly rolling at described. pace. report see net many continuing that nothing say month-to-month. steady a

Justin Klee

Yes.

slowdown address And as driven have well. there primarily by great were Jim reiterating we in Margaret to what well adds discontinuation. was that and saying, think as opportunities new I for think just growth as the patient saw we and we things

Marc Goodman

third increase steady quarter from new in So second on just adds. patient had a into the adds, patient quarter, to be new you clear

so pace up? that that slowing sense. Just speeding just was is us the what October, give whatever steady everything a similar of kind And same, down, is month-to-month, it was?

James Frates

steady Yes. is I'd steady. say

reacceleration And think place exceptionally saw keep through that point We're XX% centers. there, a about. Deciles, of levels in we got that where deciles was that on the very and Margaret is drug. grow that focus. focused. to talked important And we're launching up make we going so now see we've And doing back patients, what we growth, logical us want we're those centers we're a the doing, first were going down. well as we penetration a key to have the is next the roughly right, continue to here all is I it to things is the when to to key of for But that right, X to of to be into what do but where focus expand to

Marc Goodman

is comment it this to steady, the make quarter. maybe past but October means quarter opportunity happened here's you like know it, previous that steady was to just because you trends, exception kind I normally an this don't on given say of like do fair steady time. But what it could an

James Frates

been Yes. drug. on X% range, is on remain factor that's the have is we right? closer higher the the of people the expectations. right? -- to here, free additional going right, Well, another -- think, and we at if would a those not XX% had XX% of lot is, if Marc, So instead people's range folks were trouble right, I This an that sales

at think I levels. month-to-month, these still matter single months even So

where very going we're to the only we're to sit we be end and of quarter today. at into where the predict quarter, hard so the X And month it's

Operator

question Suvannavejh from from next And Graig Mizuho the comes Partners.

Graig Suvannavejh

X, got I Graig could. It's I've Suvannavejh. if

of the think you First, the do color lot non-ALS with to And I'm help what think now? my I or a growth question because around is you that really by this, wondering patients, you additional pace maybe second you not just up there non-ALS if you feel words, just over you do was think some other of understand product, to know you're views provide then In growth going drive maybe I element getting to PHOENIX, patients second of it's will that that about And with penetrate enter whether now PHOENIX? you which and the end be now has experiencing focused PHOENIX around above setting. if event. can capture of the setting? on wondering us more and could of a if quarter is kind do as if much usage with you And positive being anticipation data able current physicians you how right center feel that,

Margaret Olinger

Great. Yes.

that So bucket just coming in about the of certainly, One have treating that physicians as have opportunity we we in they any already focus growth see we've alivio different to They're centers. patients. are question, ALS. X -- patients but and of for their is we patients patient available within top XX% are XXX of prescribing any believe continued on drug answer buckets. your all first ALS talked about, treatment with prescribing their do X/X our we

be believe foundational So that's a heavily that we and XX% just the to we product growth opportunity education can And the approval on to function have first And us in that our only are survival. in reiterate, treatment. really front full U.S. we plus we have again, of driving focused

were in our data, We are studied therapy. we and combination confident and monotherapy to sent in our

we believe amount we've that So in just there's of heavily alone, opportunity. where on, been bucket concentrated a tremendous that and focused

you take as we've bit probably but of the tactics treatment. a we're they strategies lot haven't because some we'll second of in into bucket, identified impact They how we and specialists little work hard had in trying tools our to we're bit as have landscape have literally, on number change that in our growing function we have should is treatment quickly the think mentioned, had focused It's ALS treatment do that we've we'll with impact non-ALS on. survival. a appetite to their exactly it The and living where of implement an that tool we'll mentioned, benefits to to predict of transforming believe have the an past, little started a on a time. Justin that. will really every and access patient from that that, and absolutely of And be And elastic

believe and on And moving the for function we on in for driving learnings being long but AL really we learnings therapies not that's term. the efficacy efforts, from of our the have only comes a be opportunity we taking would us Canada, the persistency, amount with third the But have survival. long-term So the focusing tremendous taking really educational forward. bucket the

that's that impact So the regarding second then question our a an PHOENIX have lot will there. focus And our readout. doing for preparation We believe us. on is we're data. this of PHOENIX in

for. generation successful it to point incredibly of PHOENIX an have a what on use our We an demand data. we're That's perspective. duration inflection our data. both we and bullish we're on going believe from planning will certainly awareness believe And are and have business We

Operator

Ghosh And question from Wainwright next Ananda comes the H.C. with Company.

Ananda Ghosh

questions the questions. of -- I have One X

looks on in is kind the of of next specialists. center they aware with nonspecialists My strategy with question the hindrance quarter? a of you And the much what's your is the terms the PHOENIX of The data to how what the first about around uptake the absence one kind educating think about data? respect relieve like are is based nonspecialists, as

Joshua Cohen

key the you I to in with we're ALS I Well, those start mean think roughly particularly centers. great year And RELYVRIO with I question. off yes, for XX% maybe have a we launch, on the to thank clarify, into specialists. -- with people a mean,

focuses But on launch. year there's Now and interventions, there that's into obviously, that that to mostly historically a for we're meaningful good I more when symptom say, you to think do. management, trying no, think ALS quite are

in we centers. growth But more where talked that's key the obviously opportunities see we've Now do. there's work -- to those again, about for

little you is ALS patients. disease people, very very for In true. are terms and centers, that think no give we not nontherapeutic ALS can of of reminding many for obviously wants those to therapeutic they that the because a med time in landscape. just, means transform last interventions these that's there's school, think, and to learned that's a And it about They're non-key one everyone, do I meaningful. what diagnosis But

deal. trial all that on major a increasing will studies lifespan. having a first the top PHOENIX positive of, a on think ALS central top well first results course, is On the because, we of showed again, treatment with is the X the of be those as the of benefit as disease results, things, both slowing treatment Now which time milestone big community in progression for the really

near-term have all well think PHOENIX in will further that's we key why as then that. as centers we the So accelerate of feel broader both opportunities great like the neurology And we just community.

Ananda Ghosh

Great. difference on prominent. is, quite and Canada [ exactly U.S. specific stock Canada, see which question is how rate? mean discontinuation My it's The ] different second in the can see like, the is more exactly on be you And you like in U.S. the discontinuation difference than rate. you I question what Canada that

Margaret Olinger

Yes.

thanks importance So day just is but I mentioned centers focused the Canada -- X Canada to a really the therapy. it They on concentrate market. from remaining the driving key mention of XX for And excellence. about question. comments, really on have of concentrated in

the it's it's incredibly a a then decentralized that of in easier where to HCPs a bit the to patients, U.S. communicated So which that hard little to is little and the having message more sort -- down important, control little getting them

is just be expectations achieve that well, done point done rates. is persistency important. those think certainly important have and we down on the can know I going treatment in So and messages, I better think you getting to But messaging that while we when doubling really communicating those

Operator

the Mr. time. Thank Klee. you. And this concludes the call back question to turn session at I'll this

Justin Klee

thank day. have today your you our all for you for a Thank you, good on support. and We and call joining operator, us hope

Operator

Thank conference presentation, may concluded. Thank now has call attending for you. you you disconnect The today's your now lines.

Amylyx Pharmaceuticals (AMLX) 9 Nov 232023 Q3 Earnings call transcript